You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

On this page

  1. Research recommendations
  2. Guidance into practice

Tools and resources

Tools to help you put the guidance into practice.

Research recommendations

  • Research recommendations information

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top